STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: 6beta-naltrexol-3-glucuronide

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled ✓
Not Controlled □

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

• The substance is a derivative of naltrexone and is controlled under Item 1 of Schedule I to the CDSA.

Prepared by: ________________________________ Date: June 15, 2011

Zack Li

Verified by: ________________________________ Date: __________

Mark Kozlowski

Approved by: ________________________________ Date: __________

DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: Umer Sheikh, OCS
Drug Status Report

Drug: 6beta-naltrexol-3-glucuronide

Drug Name Status: 6beta-naltrexol-3-glucuronide is the common name.

Chemical Name: N-cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine-beta-D-glucopyranosiduronic acid

Chemical structure:

Molecular Formula: C_{26}H_{33}NO_{10}

Pharmacological class / Application: Naltrexone derivative

International status:

US: The substance is not listed on the schedules to the CSA and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control. The drug is not listed on the Green List - List of Psychotropic Substances under International Control.

Canadian Status: 6beta-naltrexol-3-glucuronide is a derivative of naltrexone\(^1\) and is not listed specifically in the CDSA. Naltrexone and its hydrochloride salt are both excluded from Item 1 of Schedule I of the CDSA as sub-item 34.2, by the “but not including” part of this item. However, as a derivative of naltrexone, 6beta-naltrexol-3-glucuronide is not excluded from item 1 of Schedule I and is considered a controlled substance.

Recommendation: 6beta-naltrexol-3-glucuronide is included in item 1 of Schedule I to the CDSA and is a controlled substance.
